Slingshot members are tracking this event:

FDA Accepts NDA for Amgen's (AMGN) Etelcalcetide in Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 06, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Etelcalcetide, Secondary Hyperparathyroidism, Chronic Kidney Disease, Hemodialysis, Calcimimetic Agent